System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42150333 DOI: 10.1016/j.tranon.2026.102825

Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas.

Transl Oncol 69:102825

Authors: Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb

Affiliations

  • Department of Pathology, Institut of Pathologie Multisite, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.
  • European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Gustave Roussy, Villejuif, France.
  • CICLY - EA3738, Université Claude Bernard Lyon I (UCBL1), Lyon, France; Department of Digestive Surgery, CNR RENAPE, Hôpital Lyon Sud, Pierre-Bénite, France.
  • CICLY - EA3738, Université Claude Bernard Lyon I (UCBL1), Lyon, France; Epidemiology and Clinical Research Department, Public Health Department, Hospices Civils de Lyon, Lyon, France.
  • Instituto Português de Oncologia, Department of Medicine, Porto, Portugal.
  • KU Leuven, Department of Oncology, Leuven, Belgium.
  • Centre Léon Bérard & Université Claude Bernard Lyon I (UCBL1), Lyon, France.
  • Department of Medical Oncology and Research Center on Healthcare Performance, (RESHAPE) INSERM U1290, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Department of Pathology, Institut of Pathologie Multisite, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France; Gustave Roussy, Villejuif, France.

Abstract

Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in rare cancers: the EURACAN molecular profiling and personalized medicine pathway and the France Genomic Medicine 2025 plan (AURAGEN). The aim of this study was to describe initial findings in PM and to compare these approaches in a real-world implementation setting. Herein, we present the results from a cohort of 56 patients with PM. Females represented 55.4% of patients; mean age was 55.9 years. The European (Arcagen) study profiled 26 patients and the AURAGEN platform profiled 42 patients. Genomic sequencing was performed using Foundation Medicine for the Arcagen cohort and whole-genome sequencing (WGS) for the AURAGEN cohort. Arcagen used FFPE tissue or blood depending on material availability, whereas AURAGEN relied on fresh frozen tumor tissue with paired blood (and RNA sequencing when feasible). Both cohorts displayed a predominance of alterations in BAP1, NF2, and CDKN2A/B. One patient with an ALK::STRN fusion was treated with Alectinib. AURAGEN identified a larger number of altered genes overall, while the proportion of therapeutic targets was similar between approaches. In conclusion, comprehensive molecular profiling offers potential therapeutic strategies for PM patients. Panel-based profiling and pan-genomic WGS appear complementary in real-world practice, each with distinct strengths and limitations.

MeSH

Blood, Mesothelioma, Neoplasms, Precision Medicine, Therapeutics, Tissues, Genomic Medicine